Filing Flows › Inovio Pharmaceuticals (INO) › Q1 2025
Inovio Pharmaceuticals (INO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Inovio Pharmaceuticals (INO) reported revenue of $65K for the first quarter 2025 (Q1 2025) and -44% from the quarter before.
Inovio Pharmaceuticals, Q1 2025: revenue $65K, net loss $19.7M, operating cash flow −$26.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $65K | -44% | — |
| Operating profit | −$25.1M | — | — |
| Net earnings | −$19.7M | — | — |
| Operating cash flow | −$26.9M | — | — |
What changed
Revenue was $65K in Q1 2025, down 44% from the previous quarter.
Operating costs exceeded revenue by $25.1M, an operating margin of -38337.0%. The quarter ended with a net loss of $19.7M, wider than the previous quarter's $19.4M loss. Non-operating items added $5.4M, -27% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$26.9M. Non-cash charges added back $371K of depreciation and $1.4M of share-based compensation. Working capital and other items used $9.0M. Capital expenditures of $59K exceeded it, leaving free cash flow of −$26.9M.
Questions
What was Inovio Pharmaceuticals' revenue in the first quarter 2025?
Inovio Pharmaceuticals (INO) reported revenue of $65K for the first quarter 2025 (Q1 2025) and -44% from the quarter before.